Insulin resistance and PCOS: chicken or egg?
The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
PCOS is a common and heterogeneous endocrine disorder in women of reproductive age, frequently associated with metabolic abnormalities. It was estimated that about 75% of these subjects have an impairment of insulin action, as measured by gold standard methods. While the relationship between insulin resistance and PCOS is consistently shown by a number of studies, the mechanisms underlying its primary origin still remains an unsolved issue. Insulin resistance and the associated hyperinsulinemia can induce both the endocrine and reproductive traits of PCOS. However, androgen excess, in turn, can impair insulin action, directly and/or through several changes occurring in different tissues. Body fat excess, which is another common feature in these women, can contribute to worsening the whole picture. Nevertheless, insulin resistance may also be found in many normal-weight individuals. Endocrine and metabolic abnormalities can develop in different moments, and probably there is fetal programming of these alterations. However, a number of vicious circles, with bidirectional relationships between androgen excess and insulin resistance, and with the contribution of several other factors, make it extremely difficult to understand where this process really originates. This review summarizes available evidence on this topic, in order to better understand the complex relationships linking hyperandrogenism and impaired insulin action in women with PCOS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using gold standard procedures, it was estimated that approximately 75% of patients with PCOS had insulin resistance and that the endocrine and reproductive characteristics of PCOS can be brought on by insulin resistance [27].”
From Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial (2024) · cites this paper as [27]
In the citing paper
“Using gold standard procedures, it was estimated that approximately 75% of patients with PCOS had insulin resistance and that the endocrine and reproductive characteristics of PCOS can be brought on by insulin resistance [27].”
From Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial (2024) · cites this paper as [27]
In the citing paper
“Consequently, HOMA-IR was selected in this study as the major end point as it plays a significant role in the onset and progression of PCOS.”
From Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial (2024) · cites this paper as [27]
In the citing paper
“Insulin levels, which mainly drive these surrogate indexes, depend on several factors, not only insulin sensitivity and glucose levels. In particular, obesity, age, androgen levels, metabolism and clearance of insulin, and enzymatic degradation of the insulin–receptor complex are perhaps more valuable than insulin itself [44].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [44]
In the citing paper
“The result of all the processes described above is impaired glucose transport into cells by insulin-dependent membrane GLUT 4 transporters, reduced glycogen synthesis and decreased inhibition of hepatic gluconeogenesis. This leads to hyperglycemia and to compensatory hyperinsulinemia.”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [61]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Criteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.003 · Cited by 1,358 · cited 1×
“Based on the generally adopted Rotterdam diagnostic criteria, established in a workshop consensus of the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embriology (ESHRE) [1], it was estimated that its prevalence is at least 10% [2].”
MethodMoran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108
Biological Actions of Androgens
MOORADIAN, A. D., MORLEY, J. E., & KORENMAN, S. G. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-1-1 · Cited by 1,080
Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
Insulin Degradation: Progress and Potential*
Duckworth, W. C., Bennett, R. G., & Hamel, F. G. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0349 · Cited by 871
Stepto, N. K., Cassar, S., Joham, A. E., Hutchison, S. K., Harrison, C. L., Goldstein, R. F., & Teede, H. J. (2013) · Human Reproduction · doi:10.1093/humrep/des463 · Cited by 747
Using human genetics to understand the disease impacts of testosterone in men and women
The Endometrial Cancer Association Consortium, Ruth, K. S., Day, F. R., Tyrrell, J., Thompson, D. J., Wood, A. R., Mahajan, A., Beaumont, R. N., Wittemans, L., Martin, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0751-5 · Cited by 720
Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome
Legro, R. S., Driscoll, D., Strauss, J. F., Fox, J., & Dunaif, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14956 · Cited by 699
Research works printed but not linked: 1
- Johnson T, Kaplan L, Ouyang P, Rizza P (2012) National Institutes of Health evidence-based methodology workshop on polycystic ovary syndrome. NIH EbMW reports. National Institutes of Health, Bethesda 1:1–14. https://www.prevention.nih.gov/sites/default/files/2018-06/FinalReport.pdf. Accessed 31 Mar 2020
Cited by
Items 201–229 of 229
Metabolic environment and epigenetic programming of the early embryo in rabbit
y Rada, R. V. (2022) · theses.fr (ABES) · doi:10.70675/536319d0z3a53z4da0z808cz9ab1c3f5ac7a
Liu, X., Wang, Y., Bi, Q., Zhang, Y., Wang, S., Yang, P., Pei, J., Zhu, W., Chen, Y., Zhang, Z., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1747045
“The vicious cycle of androgen excess and IR represents a vital pathogenic link, closely associated with chronic low-grade in fl ammation and immune system dysfunction (47, 48).”
Shah, F. I., Butt, S. K., Akram, F., Shehzadi, S., Ali, H., & Sabir, S. (2026) · Reproductive Sciences · doi:10.1007/s43032-026-02105-8 · Cited by 2
“An estimated 75% of women with PCOS have some degree of impaired insulin action [ 90].”
The Potential for Polycystic Ovarian Disorder Treatment Through Drug Delivery Using Nanomaterials
Sharma, R. R., Rohilla, S., Jawla, S., Kundu, L., Kumari, P., & Rawal, N. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.32s.70
Ekici, E. M., Akçakaya, S. D., Şakar, V. S., & Çelik, Ö. M. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.72007
“…in women with PCOS (Yüksel et al. 2024), our findings showed higher BMI in those categorized with NES, which aligns with literature demonstrating associations between disturbed eating patterns and BMI (Greenwood et al. 2020; Jeanes et al. 2017; Moghetti and Tosi 2021; Stefanaki et al. 2023).”
IMPACTOS FISIOPATOLÓGICOS DA SÍNDROME DOS OVÁRIOS POLICÍSTICOS NA INFERTILIDADE FEMININA
Guimarães, K. R. P., Bahia, L. S. C., de Almeida, J. K. N., Araújo, I. D. L., Coelho, L. M., & da Silva, F. A. (2026) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v7i6.8238
Firdous, U., Nisar, M., & Iqbal, M. U. N. (2026) · The Journal of Basic and Applied Zoology · doi:10.1186/s41936-026-00584-4
“Insulin resistance is the central pathogenic factor in PCOS, driving hyperandrogenism, follicular dysfunction, and metabolic complications by stimulating ovarian androgen production and disrupting hormonal pathways like LH and VEGF signaling (Li et al., 2020; Moghetti & Tosi, 2021).”
La PCOS cambia nome, d’ora in poi si chiamerà PMOS
Moghetti, P. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01821-2 · Cited by 2
Self-citationBaidya, S., Kandel, P., Rajkarnikar, S., Makaju, H. S., Niraula, A., Tuladhar, E. T., Dubey, R. K., Raut, M., Bhattarai, A., Koirala, P., et al. (2026) · European journal of medical research · doi:10.1186/s40001-026-04690-5
“A modified steroidogenesis pathway in the ovary, induced by hyperinsulinemia, is also an extrava-gant factor that contributes to hyperandrogenism [5].”
Röblitz, S. (2026) · Journal of Molecular Endocrinology · doi:10.1530/jme-25-0211
Verde, M. L., Marrapodi, M. M., Corte, L. D., Petillo, A., Fordellone, M., Uzunçıbuk, H., Piccolo, S., Nicoletti, G., & Minervini, G. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm55373
Gut microbiota and polycystic ovary syndrome: Pathogenesis and novel therapeutic approaches
Zhu, T., Sha, Y., Wang, Q., Yang, H., & Liu, T. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128643
Deciphering the Insulin Link: Exploring Metabolic Interplay in Polycystic Ovary Syndrome
Maqbool, M., Qadrie, Z., & Ashraf, H. (2026) · Tropical Journal of Pharmaceutical and Life Sciences · doi:10.61280/tjpls.v13i4.285
Li, H., Huang, J., & Yang, D. (2026) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2026.100717
Sienicka, M., Winiarska, W., Bełcikowska-Skowron, W. R., Siegmund, A., Chrapczyńska, M., Filarecka, A., Przybyszewski, P., Przybyszewska, E., Gatniejewska, J., & Prudzic, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5856
Saka, V. P., Goswami, A., Kumar, G. V. N., Das, A. K., Nanjappan, S. K., Dodoala, S., Sharma, M., Verma, D., Gupta, P., & Kaushik, S. (2026) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2026.100864
Zou, K., Ping, Y., Wei, Q., Zhao, X., Wang, Y., Wu, D., Chen, L., Wang, S., & Feng, X. (2026) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.70477
Wang, M., Wang, C., Li, Y., Fu, H., Lu, W., Zhao, Y., Liu, J., & Hu, T. (2026) · Reproduction · doi:10.1093/reprod/xaag110
Ohanoğlu, K., Cinar, A., Tercan, C., Dağdeviren, E., Kaya, Y., Can, S., Alay, İ., Cömert, N. B., Bilirer, K. K., Gelir, B. D., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187101
“Several studies have suggested that the classic hyperandrogenic phenotypes may exhibit a less favorable metabolic profile than non-hyperandrogenic phenotypes, but findings have been inconsistent across populations and study designs [7,8].”
InfluentialYu, C., Sun, Z., Wu, Q., Zhou, Z., Chen, W., & Xu, B. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1932335
Cano-González, C. N., Herrera-Estrada, M. D. L. L., Ríos-Peña, É. M., Torres-Martínez, A. D., Carmen-Jiménez, M. D., Hurtado-Santiesteban, A. P., Rodríguez-Cisneros, G., & Aguilar, C. N. (2026) · Spectroscopy Journal · doi:10.3390/spectroscj4040020
Рубеновна, А. Л., & МИЗРОБЖОНОВНА, У. Х. (2026) · Journal of Biomedicine and Practice
TUXUMDON POLIKISTOZ SINDROMINI DAVOLASHNING YANGI IMKONIYATLARI
Рубеновна, А. Л., & МИЗРОБЖОНОВНА, У. Х. (2025) · Journal of Biomedicine and Practice
Jia, Q., Zhang, S., Zhang, L., Zhao, G., Zhu, Q., & 葛红山 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1879713
“In PMOS, dysfunction of this axis constitutes its classic and core endocrine feature, rooted in rhythmic dysregulation (17 – 22).”
InfluentialAalpona, F. T. Z., Sarker, A., Nahar, L., Robel, M. A. B., & Kamrul-Hasan, A. B. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70350
Khanom, K. A., Shetu, S. F., Ara, J., & Rahman, M. (2025) · TAJ Journal of Teachers Association · doi:10.70818/taj.v38i03.0949
Sun, Y., Chen, X., Li, Z., Cheng, H., Qiu, L., Fan, Q., & Liu, H. (2026) · BMC Women s Health · doi:10.1186/s12905-026-04941-x
吴卓, Mu, L., & Cheng, S. (2026) · Reproductive Toxicology · doi:10.1016/j.reprotox.2026.109394
Facchinetti, F., Garzon, S., & Rađenović, S. S. (2026) · Medical Hypotheses · doi:10.1016/j.mehy.2026.112241
Metadata
- Authors
- Moghetti, P., & Tosi, F.
- Affiliations
- University of Verona (IT)
- Corresponding author
- Moghetti, P.
- ORCID
- Venue
- Journal of Endocrinological Investigation
- Published
- 2020-07-09
- Volume
- 44
- Issue
- 2
- Pages
- 233-244
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W3041550542
- Cited by
- 209
- References
- 92
- Citations by year
- 2026: 30 · 2025: 32 · 2024: 36 · 2023: 48 · 2022: 47 · 2021: 15 · 2020: 1
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Endocrinological Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Università degli Studi di Verona
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Keywords
- polycystic ovary syndrome, insulin resistance, hyperinsulinemia, hyperandrogenism, excess body fat, fetal programming, metabolic abnormalities, reproductive endocrine disorders, pathogenesis
- MeSH terms
- Animals, Female, Humans, Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.